via ron banged
One exchange in the Q+A of CC sums it up. After being pressed Brus stated that for the next five reporting quarters...through the end of 2009, Crucell has contracts to deliver "in the higher end" of a range of $250 to $300 million worth of Quinvaxem. That is 230 million euros worth (at One exchange in the Q+A of CC sums it up. After being pressed Brus stated that for the next five reporting quarters...through the end of 2009, Crucell has contracts to deliver "in the higher end" of a range of $250 to $300 million worth of Quinvaxem. That is 230 million euros worth (at 1.30 exchange) or 46 million euro every quarter between now and the end of 2009. The highest the pediatrics portion has ever been is 29 million euro(today).
And how about after 2009?
"The market for Quinvaxem, acquired in 2006 through the acquisition of Berna Biotech, is expected to be around 225 million doses at the end of 2009, up from around 45 million doses last year, Chief Executive Ronald Brus said."At this moment Crucell is by far the market leader and this market is growing rapidly. We continue to maintain our market share, while the market is growing," he said."
Market for Quinvaxem at 225 million doses at end of next year would represent ,at $3.50 a dose, a market of $787 million a year. While competition may increase, Crucell should be able to add to its total in the 2010 to 2013 deals with the supranationals.
Even if Crucell's share of the market dropped to 50% (right now it is virtually 80%) for the 2010 through 2013 period, that is still $343 million a year. And the Supranationals are not going to cut back on vaccinations.
1.30 exchange) or 46 million euro every quarter between now and the end of 2009. The highest the pediatrics portion has ever been is 29 million euro(today).
And how about after 2009?
"The market for Quinvaxem, acquired in 2006 through the acquisition of Berna Biotech, is expected to be around 225 million doses at the end of 2009, up from around 45 million doses last year, Chief Executive Ronald Brus said."At this moment Crucell is by far the market leader and this market is growing rapidly. We continue to maintain our market share, while the market is growing," he said."
Market for Quinvaxem at 225 million doses at end of next year would represent ,at $3.50 a dose, a market of $787 million a year. While competition may increase, Crucell should be able to add to its total in the 2010 to 2013 deals with the supranationals.
Even if Crucell's share of the market dropped to 50% (right now it is virtually 80%) for the 2010 through 2013 period, that is still $343 million a year. And the Supranationals are not going to cut back on vaccinations.